{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T13:57:53Z","timestamp":1792936673528,"version":"4.5.0"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":["ecco-jccjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.crohns.2012.08.007","type":"journal-article","created":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T05:45:27Z","timestamp":1346996727000},"page":"517-524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Induction or exacerbation of psoriatic lesions during anti-TNF-\u03b1 therapy for inflammatory bowel disease: A systematic literature review based on 222 cases"],"prefix":"10.1093","volume":"7","author":[{"given":"Rafael","family":"Denadai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio Vieira","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Steinwurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Romiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rog\u00e9rio","family":"Saad-Hossne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2012.08.007_bb0005","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00063-009-1024-8","article-title":"Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials","volume":"104","author":"Zhang","year":"2009","journal-title":"Med Klin (Munich)"},{"key":"10.1016\/j.crohns.2012.08.007_bb0015","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1172\/JCI39143","article-title":"Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed","volume":"119","author":"Miller","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.crohns.2012.08.007_bb0020","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2008.10.060","article-title":"Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review","volume":"61","author":"Moustou","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0025","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/SMJ.0b013e3181bb554c","article-title":"Adverse cutaneous reactions induced by TNF-alpha antagonist therapy","volume":"102","author":"Borr\u00e1s-Blasco","year":"2009","journal-title":"South Med J"},{"key":"10.1016\/j.crohns.2012.08.007_bb0030","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-\u03b1 antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.crohns.2012.08.007_bb0035","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis","volume":"40","author":"Collamer","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.crohns.2012.08.007_bb0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt","year":"2007","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.crohns.2012.08.007_bb0045","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1345\/aph.1C477","article-title":"Psoriasiform eruption induced by infliximab","volume":"38","author":"Verea","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.crohns.2012.08.007_bb0050","first-page":"439","article-title":"Pustular psoriasis induced by infliximab","volume":"3","author":"Thurber","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0055","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1365-2230.2005.01882.x","article-title":"Onset of flexural psoriasis during infliximab treatment for Crohn's disease","volume":"30","author":"Peramiquel","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0060","first-page":"178","article-title":"Infliximab associated new-onset psoriasis","volume":"5","author":"Adams","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0065","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000095033","article-title":"Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview","volume":"213","author":"Pirard","year":"2006","journal-title":"Dermatology"},{"key":"10.1016\/j.crohns.2012.08.007_bb0070","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/ibd.20137","article-title":"Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist","volume":"13","author":"Angelucci","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.08.007_bb0075","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/ibd.20150","article-title":"Psoriasis during anti-tumor necrosis factor-alpha therapy for Crohn's disease","volume":"13","author":"Umeno","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.08.007_bb0080","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1346-8138.2007.00312.x","article-title":"Psoriasiform and pustular eruption induced by infliximab","volume":"34","author":"Takahashi","year":"2007","journal-title":"J Dermatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0085","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000107622","article-title":"Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy","volume":"215","author":"Passarini","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.crohns.2012.08.007_bb0090","first-page":"380","article-title":"Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series","volume":"34","author":"Cohen","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0095","first-page":"231","article-title":"Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients","volume":"80","author":"Severs","year":"2007","journal-title":"Cutis"},{"issue":"Suppl. 2","key":"10.1016\/j.crohns.2012.08.007_bb0100","first-page":"A362","article-title":"Adverse skin reactions to anti-TNF agents: a systematic review of a single center cohort","volume":"132","author":"Vandecandelaere","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2012.08.007_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","article-title":"Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients","volume":"9","author":"Wollina","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0110","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2340\/00015555-0425","article-title":"Induction of pustular lesions during infliximab therapy for Crohn's disease","volume":"88","author":"P\u00e9rez-P\u00e9rez","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0115","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.23835","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action","volume":"59","author":"Collamer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2012.08.007_bb0120","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1468-3083.2007.02335.x","article-title":"Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: a case series of four patients and guidelines for management","volume":"22","author":"Papadavid","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0125","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ibd.20450","article-title":"Guttate psoriasis induced by infliximab in a child with Crohn's disease","volume":"14","author":"Costa-Romero","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.08.007_bb0130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5070\/D31ZH0D26Q","article-title":"A case of infliximab-induced psoriasis","volume":"14","author":"Richetta","year":"2008","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.crohns.2012.08.007_bb0135","first-page":"278","article-title":"Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease","volume":"70","author":"Avila Alvarez","year":"2009","journal-title":"An Pediatr (Barc)"},{"key":"10.1016\/j.crohns.2012.08.007_bb0140","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/039463200902200331","article-title":"Psoriasis induced by infliximab in a patient suffering from Crohn's disease","volume":"22","author":"Manni","year":"2009","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0145","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5021\/ad.2009.21.1.60","article-title":"Repeated paradoxical aggravation of preexisting psoriasis during infliximab treatment for Crohn's disease","volume":"21","author":"Park","year":"2009","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0150","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2310\/7750.2008.07080","article-title":"Occurrence of plantar pustular psoriasis during treatment with infliximab","volume":"13","author":"English","year":"2009","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.crohns.2012.08.007_bb0155","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/j.1365-2133.2009.09329.x","article-title":"Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments","volume":"161","author":"Seneschal","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0160","doi-asserted-by":"crossref","first-page":"A28","DOI":"10.1016\/j.cgh.2008.08.009","article-title":"Palmoplantar pustulosis and acrodermatitis in a patient treated with infliximab for Crohn's sacroiliitis","volume":"7","author":"Wermuth","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0165","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/ajg.2008.101","article-title":"First case report of adalimumab-induced psoriasis in Crohn's disease","volume":"104","author":"Harris","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0170","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1159\/000257907","article-title":"Anti-TNF-alpha-induced psoriasis \u2014 an unusual paradox","volume":"3","author":"Sharma","year":"2009","journal-title":"Case Rep Gastroenterol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0175","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/ajg.2009.396","article-title":"Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case","volume":"104","author":"Mocciaro","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"Suppl. 1","key":"10.1016\/j.crohns.2012.08.007_bb0180","first-page":"A671","article-title":"Infliximab-induced psoriasis in pediatric Crohn disease; experience of this paradoxical skin manifestation at a tertiary centre and a potential association with a variation in the IL-23r gene","volume":"136","author":"Sherlock","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"10.1016\/j.crohns.2012.08.007_bb0185","first-page":"S672","article-title":"Risk of developing anti-TNF alpha induced psoriasis among patients With Crohn's disease: are all anti-TNFs equal?","volume":"138","author":"Parian","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2012.08.007_bb0190","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2010.07.022","article-title":"Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy","volume":"8","author":"Rahier","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0195","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/DAD.0b013e3181cb3ff7","article-title":"Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-alpha inhibitor therapy. A study of 16 biopsies","volume":"32","author":"Laga","year":"2010","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0200","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ibd.20954","article-title":"Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers","volume":"16","author":"El Shabrawi-Caelen","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.08.007_bb0205","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.gcb.2009.10.021","article-title":"Development of diffuse psoriasis with alopecia during treatment of Crohn's disease with infliximab","volume":"34","author":"Medkour","year":"2010","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0210","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/nrgastro.2010.7","article-title":"Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease","volume":"7","author":"Conklin","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0215","doi-asserted-by":"crossref","first-page":"A24","DOI":"10.1016\/j.cgh.2010.04.015","article-title":"Infliximab-induced psoriaform rash","volume":"8","author":"Goldstein","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0220","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1001\/archdermatol.2010.225","article-title":"Psoriatic skin lesions induced by certolizumab pegol","volume":"146","author":"Klein","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0225","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1525-1470.2010.01267.x","article-title":"Occurrence of pustular psoriasis after treatment of Crohn disease with infliximab","volume":"27","author":"Pourciau","year":"2010","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0230","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/MPG.0b013e3181f3d9ab","article-title":"Infliximab-induced psoriasis in children with inflammatory bowel disease","volume":"52","author":"Hiremath","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2012.08.007_bb0235","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/09546634.2010.521811","article-title":"Psoriasis and psoriatic arthritis induced in a patient treated with infliximab for Crohn's disease","volume":"23","author":"Tichy","year":"2012","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.crohns.2012.08.007_bb0240","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.crohns.2010.11.001","article-title":"Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect","volume":"5","author":"Iborra","year":"2011","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2012.08.007_bb0245","first-page":"S105","article-title":"Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 19 cases","volume":"5","author":"Guerra","year":"2011","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2012.08.007_bb0250","first-page":"S98","article-title":"Anti-TNF\u03b1 agents induce psoriasiform eruption in IBD patients: frequency and outcome","volume":"5","author":"Papamichael","year":"2011","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2012.08.007_bb0255","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5070\/D32FR4G5PZ","article-title":"New-onset psoriasis associated with adalimumab: a report of two cases","volume":"17","author":"Glenn","year":"2011","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.crohns.2012.08.007_bb0260","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","article-title":"Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature","volume":"34","author":"Cullen","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2012.08.007_bb0265","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/DAD.0b013e3181ef7403","article-title":"Psoriatic alopecia\/alopecia areata-like reactions secondary to anti-tumor necrosis factor-\u03b1 therapy: a novel cause of noncicatricial alopecia","volume":"33","author":"Doyle","year":"2011","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0270","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1002\/ibd.21643","article-title":"Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients","volume":"17","author":"Baumgart","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.08.007_bb0275","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1525-1470.2011.01521.x","article-title":"Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children","volume":"29","author":"Perman","year":"2012","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0280","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TNF-mediated inflammatory disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J Pathol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0285","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000289205","article-title":"The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions","volume":"11","author":"Sfikakis","year":"2010","journal-title":"Curr Dir Autoimmun"},{"key":"10.1016\/j.crohns.2012.08.007_bb0290","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.2007.087288","article-title":"Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"68","author":"Harrison","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2012.08.007_bb0295","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1365-2036.2009.03955.x","article-title":"Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease","volume":"29","author":"Fiorino","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.crohns.2012.08.007_bb0300","first-page":"A461","article-title":"Development of psoriasiform skin lesions under anti-TNF therapy: a common link with IL23R gene variants?","volume":"134","author":"Cleynen","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2012.08.007_bb0305","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gut.2008.163642","article-title":"Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study","volume":"58","author":"Fidder","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2012.08.007_bb0310","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2036.2009.04206.x","article-title":"Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice","volume":"31","author":"Zabana","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2012.08.007_bb0315","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2036.2009.04130.x","article-title":"The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies","volume":"31","author":"Allez","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2012.08.007_bb0320","article-title":"Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-\u03b1 inhibitors: the Mayo Clinic experience, 1998 to 2010","author":"Shmidt","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0325","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2133.1982.tb01731.x","article-title":"Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis","volume":"106","author":"Yates","year":"1982","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0330","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1067\/mjd.2003.540","article-title":"Connections between psoriasis and Crohn's disease","volume":"48","author":"Najarian","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0335","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2011.02.046","article-title":"Recent insights into the genetics of inflammatory bowel disease","volume":"140","author":"Cho","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2012.08.007_bb0340","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-alpha in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.crohns.2012.08.007_bb0345","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/08916930903510906","article-title":"Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis","volume":"43","author":"Albanesi","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.crohns.2012.08.007_bb0350","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/archderm.143.2.223","article-title":"Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions","volume":"143","author":"de Gannes","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0355","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2133.1991.tb14774.x","article-title":"Psoriasis induced by interferon-alpha","volume":"125","author":"Funk","year":"1991","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0360","first-page":"670","article-title":"Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism","volume":"164","author":"Patel","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.crohns.2012.08.007_bb0365","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00128071-200001030-00003","article-title":"Drug-induced psoriasis. Recognition and management","volume":"1","author":"Tsankov","year":"2000","journal-title":"Am J Clin Dermatol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994612003698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994612003698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/7\/7\/517\/1132007\/7-7-517.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T16:24:31Z","timestamp":1687710271000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2012.08.007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":73,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S1873994612003698"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2012.08.007","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction or exacerbation of psoriatic lesions during anti-TNF-\u03b1 therapy for inflammatory bowel disease: A systematic literature review based on 222 cases","name":"articletitle","label":"Article Title"},{"value":"Journal of Crohn's and Colitis","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.crohns.2012.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}